Ad hoc: Jerini AG: Strategic Review of Jerini Assets Completed

10 oktober 2008Jerini AG / Misc. matters / Ad hoc: Strategic Review of Jerini Assets Completed Ad hoc announcement according to §15 WpHG processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Berlin, October 10, 2008 - Jerini AG (FSE:JI4) and Shire Deutschland Investments GmbH have completed the strategic review of the assets and programs of Jerini AG, not related to Icatibant (Firazyr®), as referred to in the Offer Document published by Shire Deutschland Investments GmbH on August 13, 2008. The Jerini Supervisory Board and Management Board concluded yesterday that it is in the best interests of Jerini AG to divest Jerini Ophthalmic, Inc, JPT Peptide Technologies GmbH (JPT), and Jerini's pre-clinical projects. Jerini AG will now explore options to maximize benefits for Jerini AG from the divestment of these assets. ISIN: DE0006787476 Regulated Market / Prime Standard; Frankfurt Stock Exchange, Germany For questions, please contact: Stacy Wiedenmann Director Investor Relations & Corporate Communications Jerini AG Invalidenstr. 130 10115 Berlin T + 49 - 30 - 97893 - 285 X + 49 - 30 - 97893 - 105 wiedenmann@jerini.com www.jerini.com --- End of Message --- Jerini AG Invalidenstrasse 130 Berlin Germany WKN: 678747; ISIN: DE0006787476; Index: CDAX, Prime All Share, TECH All Share; Listed: Prime Standard in Frankfurter Wertpapierbörse, Amtlicher Markt in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Berlin, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Düsseldorf;